Johannes Streffer is Neurologist and Psychiatrist, currently VP, Head of Translational Medicine Neuroscience at UCB biopharma and Visiting Professor, Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Belgium.

He has been industry co-lead of IMI-EMIF-AD, executive committee member of IMI-EPAD and is currently member of the RIS (research and innovation strategy) group of EFPIA.

With his group in UCB he is focusing on creating an integrated translational space with clinical and biomarker sciences to support early development in support of discovery projects, thru first-in-human studies until proof-of-concept. For the biomarker aspects this continuing in the life cycle of our medicines.

Johannes was trained in Tubingen (Neurology) and Zurich (Psychiatry). He joined the industry in 2007 at Janssen R&D (Pharmaceutical companies of Johnson & Johnson) and held roles of increasing responsibility, till he joined UCB Biopharm in his current role in 2017.

Johannes has published more than 70 articles in peer reviewed journals, including Brain, Neuron, The Lancet and Nature Medicine.